Your browser is old and is not supported. Upgrade for better security.

Invest in Stark Therapeutics

Stark Tx is changing the way the world treats chronic diseases with gene therapy

What Investors Say

Invested $1,000 this round
Stark is developing a vaccine for COVID-19 targeting the nucleocapsid protein (N-protein), a well-studied vaccine target from the original SARS outbreak, but surprisingly a target that current vaccine efforts have overlooked. By leveraging the vast amount of research on the original SARS nucleocapsid, we believe Stark has identified a safe vaccine target with a low variance rate and a predictable immunogenetic response. Stark is moving at breakneck speed as they have partnered with a manufacturer, set up a lab for target production, and are looking at initiating animal trials in the next six weeks. Couple this with Anthony’s endless energy, passion, brilliance, and domain expertise, we believe Stark is a major contender to develop a COVID-19 vaccine.
What People Say